The European nanomedicines market is projected to grow at a modest CAGR of 10.9% during the forecast period (2021-2027). The major aspect that drives the growth of the market includes the rising burden of various diseases in the region. Owing to this, there has been an increased focus of the government along with other organizations regarding the development of novel treatment technologies including nanomedicines. For instance, organizations such as the European Society for Nanomedicine (ESNAM) and the European Technology Platform on Nanomedicine (ETPN) focus on promoting the research and clinical applications of nanomedicine for the betterment of humanity and the environment. Hence, the aforementioned factors are likely to drive the growth of the market in the region over the forecast period.
The European nanomedicines market is segmented on the basis of indication type and application. Based on the indication type, the market is segmented as cardiovascular diseases, neurological diseases, infectious diseases, oncological diseases, orthopedic diseases, and others. The other segment includes urological disease and ophthalmic diseases. The cardiovascular diseases segment is likely to hold a substantial share in the market over the forecast period. Based on the applications, the market is segmented as drug delivery, active implants, vaccines, diagnostic imaging, biomaterials, regenerative medicines, and other applications. The other segment includes tissue regeneration. The drug delivery segment is likely to hold a substantial share in the market over the forecast period.
Based on the demographic viewpoint, the European nanomedicine market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of European. The UK is projected to hold a significant market share over the forecast period owing to various R&D activities conducted by the key players. Further, 3M Co., Johnson & Johnson Services Inc., Merck & Co. Inc., Thermo Fisher Scientific Inc., AstraZeneca Plc., Celgene Corp., Pfizer Inc., Sanofi SA, and Smith & Nephew Plc among others are some of the prominent players functioning in the European nanomedicine market. New product launches & developments, partnerships, agreements, and acquisitions are some of the growth strategies adopted by the players in order to sustain in the highly competitive market.
RESEARCH METHODOLOGY
The market study of the European nanomedicine market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.
Secondary sources include:
The report is intended for nanomedicine companies, healthcare companies, research institutes and universities, other related companies, and government organizations for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions.
Market Segmentation:
The Report covers:
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Competitive Dashboard
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. European Nanomedicine Market by Indication Type
5.1.1. Cardiovascular Diseases
5.1.2. Neurological Diseases
5.1.3. Infectious Diseases
5.1.4. Oncological Diseases
5.1.5. Orthopedic Diseases
5.1.6. Other Diseases (Urological Disease, Ophthalmic Diseases)
5.2. European Nanomedicine Market by Application
5.2.1. Drug Delivery
5.2.2. Active Implants
5.2.3. Vaccines
5.2.4. Diagnostic Imaging
5.2.5. Biomaterials
5.2.6. Regenerative Medicines
5.2.7. Other Applications (Tissue Regeneration)
6. Regional Analysis
6.1. European
6.1.1. The UK
6.1.2. Germany
6.1.3. France
6.1.4. Italy
6.1.5. Spain
6.1.6. Rest of European
7. Company Profiles
7.1. 3M Co.
7.2. AstraZeneca Plc.
7.3. Celgene Corp.
7.4. Ferro Corp.
7.5. GE Global Research
7.6. Johnson & Johnson Services Inc.
7.7. Luminex Corp.
7.8. Merck & Co. Inc.
7.9. PerkinElmer Inc.
7.10. Pfizer Inc.
7.11. Sanofi SA
7.12. Smith & Nephew Plc
7.13. St. Jude Medical Inc.
7.14. Stryker Corp.
7.15. Thermo Fisher Scientific Inc.
1. EUROPEAN NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY INDICATION TYPE, 2020-2027 ($ MILLION)
2. EUROPEAN NANOMEDICINES FOR CARDIOVASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
3. EUROPEAN NANOMEDICINES FOR NEUROLOGICAL DISEASES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
4. EUROPEAN NANOMEDICINES FOR INFECTIOUS DISEASES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
5. EUROPEAN NANOMEDICINES FOR ONCOLOGICAL DISEASES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
6. EUROPEAN NANOMEDICINES FOR ORTHOPEDIC DISEASES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
7. EUROPEAN NANOMEDICINES FOR OTHER DISEASES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
8. EUROPEAN NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
9. EUROPEAN DRUG DELIVERY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
10. EUROPEAN ACTIVE IMPLANTS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
11. EUROPEAN VACCINES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
12. EUROPEAN DIAGNOSTIC IMAGING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
13. EUROPEAN BIOMATERIALS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
14. EUROPEAN REGENERATIVE MEDICINES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
15. EUROPEAN OTHER APPLICATIONS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
16. EUROPEAN NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
17. UK NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY INDICATION TYPE, 2020-2027 ($ MILLION)
18. UK NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
19. GERMANY NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY INDICATION TYPE, 2020-2027 ($ MILLION)
20. GERMANY NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
21. FRANCE NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY INDICATION TYPE, 2020-2027 ($ MILLION)
22. FRANCE NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
23. ITALY NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY INDICATION TYPE, 2020-2027 ($ MILLION)
24. ITALY NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
25. SPAIN NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY INDICATION TYPE, 2020-2027 ($ MILLION)
26. SPAIN NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
27. REST OF EUROPEAN NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY INDICATION TYPE, 2020-2027 ($ MILLION)
28. REST OF EUROPEAN NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
1. EUROPEAN NANOMEDICINE MARKET SHARE BY INDICATION TYPE, 2020 VS 2027 (%)
2. EUROPEAN NANOMEDICINE MARKET SHARE BY APPLICATION, 2020 VS 2027 (%)
3. EUROPEAN NANOMEDICINE MARKET SHARE BY COUNTRY, 2020 VS 2027 (%)
4. UK NANOMEDICINE MARKET SIZE, 2020-2027 ($ MILLION)
5. GERMANY NANOMEDICINE MARKET SIZE, 2020-2027 ($ MILLION)
6. FRANCE NANOMEDICINE MARKET SIZE, 2020-2027 ($ MILLION)
7. ITALY NANOMEDICINE MARKET SIZE, 2020-2027 ($ MILLION)
8. SPAIN NANOMEDICINE MARKET SIZE, 2020-2027 ($ MILLION)
9. REST OF EUROPEAN NANOMEDICINE MARKET SIZE, 2020-2027 ($ MILLION)